(Total Views: 592)
Posted On: 06/10/2022 5:38:57 PM
Post# of 156228
We don’t have the full picture when it comes to NASH so wait and see. We’ve always had to do a phase 3. Didn’t matter how good the results were. We still need a partner to conduct the trial.
Let’s say we start a phase 3 with a big partner we won’t see much more than 1-3 Billon market cap. Better than where we are at. I’d assume we will stay around 1-3 dollars.
Personally until the BLA is done I don’t think we see double digits. Even with partners and phase 3 trials being conducted. Maybe short lived but until we have revenue and an approval we will not see any substantial market cap for awhile imo. Meaning 10 Billon plus.
Sorry if this post is all over the place, exhausted, but I think people understand what I’m trying to say.
Regardless I do not believe these prices will last. We will find a new bottom to talk about hopefully being around 3 dollars.
Let’s say we start a phase 3 with a big partner we won’t see much more than 1-3 Billon market cap. Better than where we are at. I’d assume we will stay around 1-3 dollars.
Personally until the BLA is done I don’t think we see double digits. Even with partners and phase 3 trials being conducted. Maybe short lived but until we have revenue and an approval we will not see any substantial market cap for awhile imo. Meaning 10 Billon plus.
Sorry if this post is all over the place, exhausted, but I think people understand what I’m trying to say.
Regardless I do not believe these prices will last. We will find a new bottom to talk about hopefully being around 3 dollars.


Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com